Join Our Mission: Contract Fundraiser for a Medical Non-Profit

Are you passionate about making a difference in healthcare? We are a small but dedicated non-profit medical association committed to educating clinicians and lawmakers about the benefits of cannabinoid medications to improve patient care. Our mission serves patients of all ages, from children to seniors, ensuring they receive the best possible care.

Hemp is seriously complicating the cannabis world.  This is making it harder to treat patients and to safeguard the public health.  There is a range of historical reasons that have led us to this quagmire but regardless of the history and rationale, we have to understand the current situation and how that affects our patients.  

Association of Cannabinoid Specialists (ACS) proposes that the term “adult-use” be changed to “non-medical use” in all communication, laws, and regulation.  The term “adult-use” is inaccurate, stigmatizing, and harmful to the community whereas “non-medical use” is accurate, supportive, and will decrease confusion among consumers.

Recently the FDA has sent a warning letter to a California company for marketing an injectable CBD product.  As reported via a variety of outlets, FDA cited multiple legal infractions and gave the company 15 days to comply with all laws and regulations.  Further legal action, of any unspecified nature, was implied in the letter if compliance was not ensured by the due date.  

The cannabis industry is growing at an unprecedented pace, driven by the legalization wave across the globe. However, as the market expands, so too does the need for robust testing to ensure the safety, quality, and consistency of products. 

While cannabis has garnered significant attention for its unique ability to interact with the human Endocannabinoid System, maintaining the health and balance of this vital system can be achieved or supported in ways that are not simply consuming cannabis. A holistic approach that encompasses diet, lifestyle, and therapeutic practices can produce the best results.

The concept of Clinical Endocannabinoid Deficiency (CED) is a hypothesis that suggests an underactive endocannabinoid system (ECS) may contribute to the pathogenesis of certain chronic conditions.

You’re scrolling through your news feed and you come across an announcement about a new study that claims cannabis use causes heart disease.

Should you believe it? Is it trustworthy? How can you tell?

As the legalization of cannabis continues to spread across the United States, a critical concern that has emerged is the increase in driving under the influence of cannabis. This trend poses significant challenges to road safety and public health. Understanding the implications of cannabis-impaired driving is essential for both policymakers, patients, and the general public.